Axonics Provides Survey Results from Physician Seminar Series Showcasing the Recently FDA Approved Axonics r-SNM System - Seite 2

Cohen continued, “It is worthwhile to note that clinical efficacy is the most important consideration for selecting an SNM supplier amongst these physicians. In this regard, the 90% efficacy achieved for all implanted subjects in our pivotal clinical study will serve us well as we work diligently to convert more accounts to Axonics. We are pleasantly surprised that 96% of all attendees anticipate seeing double digit growth in SNM implant volume. This is consistent with our thesis that the market will expand greatly over the coming years, and that Axonics will instigate this growth. Since we started shipping in the U.S. on October 28, demand for our product has been brisk and we expect to see this continue into 2020. “

About Axonics Modulation Technologies, Inc. and Sacral Neuromodulation

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Company’s website at www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005259/en/